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Slow-CT* are fused. Around the tumor will appear its movement blurring, it is the ITV. (g) We design treatment on the Slow-CT*.
(h) In the ConeBeamCT the tumor blurring must not exceed the PTV. (i) Patient is treated on Elekta-Synergy linac. (j) After every
treatment we repeat the acquisition IGRT and check the modiﬁcations during the treatment.
Results. Up to date a total of 10 patients have been treated, 9 primary tumors and a local relapse: 3–5 sessions and 40–50Gy dose
range. CT/PET images show complete response in 8 patients after 6 months. There were no G3 pneumonitis and no G2 esophagus
toxicity. The systematic error of intra-fraction movements were 0.4mm, 0.5mm and 0.9mm (x,y,z) and the random error were
0.5mm, 0.5mm and 1mm (x,y,z). Only in one patient the treatment time exceeded 12min.
Conclusions. ExaCradel and ConeBemaCT form a precise and rapid system as SBRT technology.
http://dx.doi.org/10.1016/j.rpor.2013.03.542
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Hypothalamic hamartomas (HH) arise as a result of an incorrect embryonic cell migration. Most patients with a HH are asymp-
tomatic. Gelastic seizures in association with HH were described some years ago and the majority of these patients present
medically refractory epilepsy. They can develop a severe epileptic encephalopathy associated to behavior and cognitive disor-
ders and precocious puberty (related to secretory granules). Surgery can be an effective treatment but it has been related to
important morbidity and mortality because of their location and relation to critical structures (optical pathways). The objective
of the present study is to evaluate our results with Gamma-Knife surgery (GKS) treatment in these lesions. Methods. We have
treated by GKS 30 patients with HH from 2002 to nowadays. We retrospectively reviewed our prospectively collected data and
analyze 23 of these patients. This series includes 14 women and 9 men, presenting lesions from 8cc to 0.2 cc. Mean age was 17
years old (ranged: 16 months to 45 years). For diagnosis and planning Video-EEG, CT and stereotactic MRI (T1, T2, Flair and T1
post-gadolinium, using axial, coronal and sagittal sections) were used.
Results. 8 cases had been operated previously. The mean coverage dose has been 18.5Gy. More than 70% of the patients had
a positive outcome, even though most of them still need medication. After 2 years follow-up, 5 cases were re-treated due to
medically refractory symptom persistence or reappearance. The mean coverage dose used was 17Gy. In 2 of these 5 patients a
favorable evolution was observed.
Conclusions. In the treatment and control of medically refractory epilepsy secondary to HH we considered GKS as an effective,
safe and reliable option. Prognostic factors that should be considered are evolution time (the precocity of treatment) and other
epileptic focus absence. Other factors are lesion size and relation-distance between the HH and the critical structures. The
possibility of achieving a correct coverage dose of more than 17Gy irradiating the entire lesion depends of them. These facts
have been conﬁrmed in our series.
http://dx.doi.org/10.1016/j.rpor.2013.03.543
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Objective. LINAC-based radiosurgery is commonly used for trigeminal neuralgia treatment. Due to the small size and spherical
or elliptical geometry of the target, small cones are suitable for this technique.
Materials and methods. A radiosurgery cone set (Brainlab) of diameter 5, 6, 7.5 and 10mm was modelled for a 6MV linac PRIMUS
(Siemens). Reference dose was measured using a camera PTW Farmer type 30013. Output factor, PDDs and OARs were measured
for each cone in a PTW water phantom MP3 using a diode detector PTW 60012. Correction in output factors is up to 6% for the
cone of 5mm. For commissioning the TPS: accuracy of monitor units (MU) calculations, isocentre localization, punctual dose
with MOSFET, and dose proﬁles with Gafchromics ﬁlms.
Results. We performed several veriﬁcations: (1) Manual calculation of MU performed with measured data shows a maximum
difference of 1.3%. (2) We used a Gafchromic EBT2 placed in the stereotactic localizer with a pin to locate isocentre. After a CT
scan, pin delineated and used like isocentre to deliver the treatment. Isocentre localization was less than 0.5mm. (3) We scanned
an anthropomorphic Alderson Rando phantom head with a MOSFET detector placed inside. We localized the CT scan using
iPLan, marked the isocentre at the MOSFET and delivered treatment. The dose agreement was for the 10-mm cone, lesser than
5% (MOSFET uncertainty: 3%). (4) A ﬁlm was placed at depth of 15mm in a water phantom and an arc of 120◦ was delivered. We
compared measured data with TPS calculation using OmniPro® (IBA). A good agreement is showed for inplane and crossplane.
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Conclusion. The most accurate and reliable method for measuring relative dose are ﬁlms. Diodes and MOSFET can be used for
output factor measurements, but corrections must be taken into account. Results are consistent and the ﬁrst clinical results
indicate a favourable evolution.
http://dx.doi.org/10.1016/j.rpor.2013.03.544
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Purpose. In this study we report our ﬁrst clinical results of prostate motion management during stereotactic gated RapidArc
treatment and a novel application, IntrafractionMotion Review (IMR, Varianmedical systems) allowing kV/MV images acquisition
during dose delivery.
Methods and materials. Seven prostate cancer patients were treated using the gated RapidArc technique with a Varian Novalis
Truebeam linear accelerator. Before treatment simulation, three gold ﬁducial markers and Hialuronic Acid were implanted inside
the prostate using transrectal ultrasound guidance. A computed tomography (CT) was registered with a MR acquisition for
simulation. Treatment planning was realized on an Eclipse workstation with PRO 3 algorithm V 10.0.28. Dose delivery consists
on 2 arcs using Rapidarc modality with 600MU/min maximum dose rate on a Novalis Truebeam linear accelerator. An equivalent
dose of 84Gy over 20 fractions at 3.1Gy/fraction was delivered. Before the treatment delivery, the RPM block placed on patient’s
abdominal surface generate the gating signal use for IMR acquisition on V1.6 of Truebeam. Then, the patient’s alignment is set
based on markers using daily cone beam CT (CBCT) and kV/kV matching. During the treatment, kV images were acquired at
each exhale phase of the breathing cycle and the positions of the ﬁducial markers were compared with their expected positions
represented by a green circle with a diameter corresponding to the ﬁducial length. We reported here for the six ﬁrst patients
the differences between expected and real ﬁducial position. The treatment delivery parameters such as number of kV images
acquired per fraction, the fraction’s time and the room occupation’s time were also mentioned.
Results. Fraction time delivery (time to deliver the total dose) was 16±6min. The number of KV images acquired during VMAT
delivery is 26±15 with a maximum of 64. Average deviation in cranio caudal direction was analyzed on each images resulting in
a mean deviation of 0.29 [0–1.4]mm. Antero posterior or lateral shifts are difﬁcult to analyzed in a post processing phase as they
are not visible on all KV images but online correction with a shift of ﬁducial outside the green circles was necessary for only 2
sessions on 120.
Conclusion. IntrafractionKVveriﬁcation is possiblewith the IMRsystemavailable onTruebeam. Increase in time sessionacceptable
even if the process must actually be associate to a respiratory gate treatment. New version of the software in the next future will
allow this kind of online veriﬁcation without the need of RPM system.
http://dx.doi.org/10.1016/j.rpor.2013.03.545
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Purpose. Determine the impact of treatment with SBRT with curative intent in the evolution of the disease in oligometastastatic
patients treated in our center.
Methods. Between 2008 and 2012, 7 patients with less than 5 metastatic lesions and primary controlled were enrolled on prospec-
tive studies of SBRT for oligometastases. All available records were retrospectively reviewed to determine the evolution of the
disease. The hystologies were: 1 endometrium, 1 breast cancer, 2 prostate, 2 GI ADC, 1 NSCLC. The location of oligometastasis
were: 2 spine, 4 bone, 1 liver, 2 lung, 1 retroperitoneum. All patients has ECOG 0-1. The median age was 64 years, median time
from diagnosis of the primary diagnosis of metastases was 4.7 years. PTV volume of the lesions was between 13 cc and 55 cc,
the doses administered were 21Gy in 3 fx to 60Gy to in 5 fx. In all cases the technique was guided by CBKvCT image after CT
simulation, fusion with PET/CT and/or MRI, and calculation, 4 with 3DRTE and 3 with IMRT. The toxicity was reported with the
CTCAE.4 scale by site.
Results. With a median follow-up of 27 months (4–50), the results in terms of local control after treatment of metastases were
80% (2 local progressions and treated again with SBRT, and 1 distance progression treated with chemotherapy). All patients are
alive and maintain his ECOG at the time of the study. The improvement of symptoms was 90%. The toxicity reported in all the
patients was less than G2 in CTCAE.4 scale by site. No chronicle toxicity was reported.
Conclusions. Among this limited experience, SBRT is a good option in oligorecurrent patients, and perhaps may yield prolonged
survival, cure or chroniphy the disease in select patients with limited metastases.
http://dx.doi.org/10.1016/j.rpor.2013.03.546
